Barriers to Alzheimer disease drug discovery and development in the biotechnology industry

Alzheimer Disease and Associated Disorders

Volumn 16, Issue SUPPL. 1, 2002, Pages

  Altstiel, Lary D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer disease; Biotechnology; Drug development

Indexed keywords

ALZHEIMER DISEASE; BIOTECHNOLOGY; DISEASE COURSE; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0036279726     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200200001-00005     Document Type: Review

References (28)

1. Drug discovery in the new millennium: The pivotal role of biotechnology
2. The importance of genome analysis to the drug discovery process
3. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum
4. Molecular genetics of Alzheimer's disease
5. The impact of genomics on drug discovery
6. The Alzheimer's Disease Assessment Scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials
7. Drug discovery: A historical perspective
8. Combinatorial chemistry as a tool for drug discovery
9. Worldwide prevalence and incidence of dementia
10. The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop
11. Drug development history, overview, and what are GCPs?
12. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
13. Drug discovery: Past, present and future
14. Strategies and recent technologies in drug discovery
15. Slowing the progression of Alzheimer disease: Methodologic issues
16. Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease
17. Rational design of an animal model for Alzheimer's disease: Introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent
18. The relationship between apolipoprotein E, dementia, and vascular illness
19. Drug discovery in the next millennium
20. Alzheimer's disease: Genetic studies and transgenic models
21. Utilization of genetically altered animals in the pharmaceutical industry
22. Drug discovery and development in the pharmaceutical industry
23. Transgenic approaches to model Alzheimer's disease
24. Link between heart disease, cholesterol, and Alzheimer's disease: A review
25. From genome to drug-optimising the drug discovery process
26. Recent developments in the drug treatment of Alzheimer's disease
27. Pharmaceutical proteomics
28. Drug firms need biotech drug discovery